SCHEMBL4118804

SCHEMBL4118804

Cc1cccc(S(=O)(=O)c2cc(CCNC(=O)O)nn2-c2ccccc2Cl)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
NPC1 O15118 3/20 0.35
TP53 P04637 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HPGD P15428 2/20 0.35
RAB9A P51151 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MITF O75030 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CNR1 P21554 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4125307 0.89 NFE2L2 (0.38) SMN1; SMN2TP53ALDH1A1MEN1KMT2A
SCHEMBL4126579 0.86 SLC16A3 (0.41) LMNASMN1; SMN2ALDH1A1RAB9AMEN1
SCHEMBL4119656 0.84 P2RX7 (0.39) SMN1; SMN2NPC1TP53ALDH1A1HPGD
SCHEMBL4135868 0.83 NAMPT (0.39) LMNASMN1; SMN2NPC1ALDH1A1RAB9A
SCHEMBL4135079 0.83 SLC16A3 (0.37) LMNASMN1; SMN2NPC1TP53ALDH1A1
SCHEMBL4118797 0.83 SLC16A3 (0.36) LMNASMN1; SMN2NPC1TP53ALDH1A1
SCHEMBL4125774 0.82 SMN1; SMN2 (0.36) LMNASMN1; SMN2ALDH1A1CNR1SLC16A3
Hydrochloric Acid SCHEMBL4131384 0.82 HTR6 (0.36) LMNASMN1; SMN2NPC1TP53ALDH1A1
SCHEMBL4125459 0.82 ATM (0.36) SMN1; SMN2NPC1TP53ALDH1A1HPGD
SCHEMBL4126274 0.80 GAA (0.40) LMNASMN1; SMN2NPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2190822-B1 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-12-31 EP disclosed
US-20090156642-A1 5-Membered heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156642-A1 5-Membered heterocyclic compound CEL, PGA5, COG5 LMNA 4283/4885SMN1; SMN2 4327/4885NPC1 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.